Table 2 Univariate analysis of progression-free survival and overall survival of patients receiving chemotherapy (CT) with platinum plus pemetrexed (n = 51).

From: ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients

 

PFS

P valuea

OS

P valuea

Age ≤ 50 versus > 50 years

0.80 (0.43–1.52)

0.502

0.71 (0.30–1.70)

0.443

Female versus male

1.87 (1.00–3.49)

0.051

1.76 (0.76–4.08)

0.190

NS versus C/FS

1.28 (0.69–2.39)

0.439

1.61 (0.65–3.96)

0.305

ECOG PS 0–1 versus 2–4

0.85 (0.26–2.80)

0.789

0.23 (0.05–1.10)

0.065

Brain metastasis no versus yes

1.69 (0.82–3.46)

0.153

1.73 (0.59–5.12)

0.322

CT 1st line or not

0.82 (0.34–1.97)

0.661

1.07 (0.32–3.63)

0.915

Cisplatin versus carboplatin

0.78 (0.48–1.27)

0.318

0.65 (0.37–1.12)

0.119

PD-L1: positive versus negativeb

0.82 (0.42–1.61)

0.560

0.79 (0.30–2.07)

0.635

ALK variants V3a/b versus othersc

1.44 (0.57–3.66)

0.445

4.24 (1.18–15.21)

0.026

  1. PFS progression-free survival, OS overall survival, NS non-smokers, C/FS current/former smokers, ECOG PS Eastern Cooperative Oncology Group Performance Status, CT chemotherapy.
  2. aBy logistic regression model; presented by hazard ratio (95% CI).
  3. bAvailable in 45 patients.
  4. cAvailable in 24 patients.
Back to article page